EU secures additional 100 million doses of Pfizer-BioNTech vaccine for 2021 delivery
Extra supply will bring total number of doses scheduled to be shipped to EU this year to 600 million
The European Union has secured another 100 million doses of the Pfizer-BioNTech COVID-19 vaccine, Comirnaty, for delivery in 2021 after activating a clause in an existing supply contract, the two companies said Monday.
The European Commission’s decision to exercise an option in the advance purchase agreement signed in February brings the total number of doses of the vaccine to be delivered to the 27 EU member states this year to 600 million.
“We now intend to deliver a total of 600 million doses to the EU this year, which covers two thirds of the EU population and represents the largest cumulative supply agreement for Comirnaty that we have agreed to date globally,” said Sean Marett, Chief Business and Chief Commercial Officer of BioNTech.
Pfizer CEO, Albert Bourla, said to date the company had met all of it supply commitments to the EC and planned to deliver 250 million doses to the EU in Q2, “a four-fold increase on Q1’s agreed quantity.”
Back in January, shipments of the vaccine to the bloc were affected by what Pfizer and BioNTech said were changes to the manufacturing processes designed to increase production capacity, but at the time the companies insisted the bottlenecks were only temporary.
The EU has been looking to offset the impact of delays to Johnson & Johnson’s single-shot vaccine, after US regulators review links to rare cases of blood clotting, as well as several member states’ decisions to restrict usage of AstraZeneca’s vaccine.
Last week, the Danish Health Authority removed the AstraZeneca shot entirely from its inoculation programme, saying that based on scientific findings, it had determined there was a real risk of severe side effects with using it.
Related News
-
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio -
News Sharp seeks greater foothold in Chinese market through ClinsChain partnership
Sharp hopes teaming up with clinical service provider ClinsChain will open the door to the Chinese market -
News GSK spins off consumer arm Haleon in biggest European listing for a decade
Haleon becomes the world’s biggest consumer health business, but debuted with a lower-than-expected valuation -
News SIGA reports $28M worth of new orders for monkeypox antiviral
The company has seen a sharp uptick in orders for its oral treatment as monkeypox cases rise globally -
News New CPHI report looks at CDMO outsourcing and partner selection
In The Future of Outsourcing - Strategies for Partner Selection, experts from across the pharma industry look at current trends impacting the contract services landscape and gauge the merits and drawbacks of the most common outsourcing strategies ... -
News CureVac files patent infringement lawsuit against BioNTech over mRNA technology
Company is seeking ‘fair compensation’ for alleged infringement of intellectual property rights relating to the use of mRNA tech to create the Pfizer-BioNTech COVID-19 vaccine
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance